Project details – Deep Dive B.

Payer value assessment for an advanced-therapy medicinal product (ATMP) to support Series C financing and first EU payer interactions

After publishing promising clinical data for a novel gene therapy, a biotech company was preparing for Series C financing to fund pivotal trials and expand into earlier treatment settings. During preliminary investor discussions, the company faced pushback on its European pricing and access assumptions, raising concerns about payer willingness to fund high one-time therapies in evolving reimbursement frameworks.

Experience from comparable ATMP and early-launch projects has shown the importance of establishing a realistic view of the European pricing, access, and funding environment early on.
Benchmarking of gene therapy launches and targeted expert dialogues, including payer-advising clinicians, former payers, and funding specialists, can provide valuable external validation of value narratives and assumptions. They can even suggest adaptations to clinical study and/or real world-evidence programs.
These insights illustrate how Convalentis Access Architecture™ helps innovators connect value communication, evidence planning, and stakeholder readiness ahead of market entry.

Such early assessments typically refine pricing and access projections, enabling biotech leadership to optimize their evidence plans and to defend their commercial assumptions more confidently in investor discussions. It also provides a roadmap to de-risk access uncertainties over time — strengthening both investor confidence and organizational readiness.

For biotech startups, early access thinking is not optional, it’s strategic capital.